{"schema_version":"secwatch.filing_event.v1","accession":"0000885725-23-000024","form_type":"8-K","ticker":"BSX","cik":"0000885725","company_name":"BOSTON SCIENTIFIC CORP","filed_at":"2023-04-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.614843+00:00","generated_at":"2026-06-16T14:52:38.228351+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Boston Scientific Q1 beat: sales $3.39B (+14% organic), adj EPS $0.47, guides up","bullets":["Q1 net sales $3.389B (+14% organic vs guide 6-8%), GAAP EPS $0.21, adjusted EPS $0.47 vs guide $0.42-0.44.","Cardiovascular +15.9% operational; MedSurg +13.4%; U.S. +12.7%, EMEA +20% operational.","FY23 organic sales growth guidance raised to 8-10%; adjusted EPS forecast $1.90-$1.96.","Q2 guidance: organic sales +7-9%; adjusted EPS $0.48-$0.50.","Closed acquisitions of Apollo Endosurgery and majority stake in Acotec; FDA clearance for LithoVue Elite."],"urls":{"canonical":"https://secwatch.observer/filing/0000885725-23-000024","json":"https://secwatch.observer/filing/0000885725-23-000024.json","markdown":"https://secwatch.observer/filing/0000885725-23-000024.md","text":"https://secwatch.observer/filing/0000885725-23-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/885725/000088572523000024/0000885725-23-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/885725/000088572523000024/bsx-20230426.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T14:52:38.228351+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1e381fa8e66442ebb19a89db43e0df678bbdba41","claim":"BOSTON SCIENTIFIC CORP reported first quarter ended March 31, 2023 results: revenue $3.389 billion, net income $300 million or $0.21 per share (EPS), compared to $97 million or $0.07 per share a year ago, and achieved adjusted EPS, EPS $0.21 per share.","evidence_excerpt":"RELEASE BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FIRST QUARTER 2023 Marlborough, Mass. (April 26, 2023) -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.389 billion during the first quarter of 2023, growing 12.0 percent on a reported basis, 14.9 percent on an operational 1 basis and 14.0 percent on an organic 2 basis, all compared to the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/885725/000088572523000024/0000885725-23-000024-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$3.389 billion"},{"label":"Net income","value":"$300 million or $0.21 per share (EPS), compared to $97 million or $0.07 per share a year ago, and achieved adjusted EPS"},{"label":"EPS","value":"$0.21 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}